Renaissance Group LLC Invests $7.17 Million in GeneDx Holdings Corp. $WGS

Renaissance Group LLC bought a new position in GeneDx Holdings Corp. (NASDAQ:WGS) during the 4th quarter, Holdings Channel reports. The fund bought 55,103 shares of the company’s stock, valued at approximately $7,167,000.

Several other large investors have also recently made changes to their positions in WGS. Jones Financial Companies Lllp increased its holdings in shares of GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares during the last quarter. Quarry LP grew its position in GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after acquiring an additional 209 shares in the last quarter. Ramirez Asset Management Inc. purchased a new position in GeneDx in the fourth quarter worth about $33,000. Bank Julius Baer & Co. Ltd Zurich purchased a new position in GeneDx in the fourth quarter worth about $35,000. Finally, Gordian Capital Singapore Pte Ltd purchased a new position in GeneDx in the third quarter worth about $65,000. 61.72% of the stock is owned by institutional investors.

Insider Activity at GeneDx

In other GeneDx news, Director Keith A. Meister bought 533,758 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was acquired at an average price of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the transaction, the director directly owned 3,761,908 shares of the company’s stock, valued at approximately $142,425,836.88. This represents a 16.53% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Casdin Capital, Llc bought 185,000 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were acquired at an average price of $42.60 per share, with a total value of $7,881,000.00. Following the transaction, the director directly owned 3,367,164 shares of the company’s stock, valued at approximately $143,441,186.40. This trade represents a 5.81% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 2,256,420 shares of company stock valued at $93,144,340 and have sold 72,382 shares valued at $4,889,473. 29.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

WGS has been the subject of several recent research reports. Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. Wall Street Zen lowered GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Jefferies Financial Group set a $150.00 price target on GeneDx in a research report on Monday, February 23rd. Weiss Ratings lowered GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $130.00 price target (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, GeneDx currently has an average rating of “Moderate Buy” and a consensus target price of $96.43.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Casdin Capital disclosed purchases of 150,000 shares and 50,000 shares of GeneDx, which may signal that at least one investor sees value after the recent selloff. Casdin Capital, Llc Acquires 150,000 Shares of GeneDx (NASDAQ:WGS) Stock Casdin Capital, Llc Acquires 50,000 Shares of GeneDx (NASDAQ:WGS) Stock
• Neutral Sentiment: GeneDx presented at Goldman Sachs’ 47th Annual Global Healthcare Conference, which can keep the company in investor focus but did not include a major new business announcement. GeneDx Holdings Corp. (WGS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Multiple law firms announced or promoted class-action lawsuits against GeneDx, with allegations that the company and executives made false or misleading statements to investors during the April 2025 to May 2026 class period. WGS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
• Negative Sentiment: The lawsuits center on a sharp stock decline after GeneDx’s Q1 2026 earnings miss and a major write-off tied to the Fabric Genomics acquisition, which has heightened legal and reputational risk for the company. GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition – Hagens Berman

GeneDx Stock Down 3.6%

Shares of NASDAQ:WGS opened at $54.32 on Thursday. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87. The business has a 50 day simple moving average of $55.13 and a two-hundred day simple moving average of $91.01. The firm has a market capitalization of $1.61 billion, a PE ratio of -20.27 and a beta of 1.96. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The business had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. During the same quarter last year, the firm earned ($0.23) EPS. On average, equities analysts predict that GeneDx Holdings Corp. will post -1 EPS for the current year.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.